{"product_id":"biolifesolutions-marketing-mix","title":"BioLife Solutions Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how BioLife Solutions tailors its cold-chain products, premium pricing, targeted distribution to biopharma partners, and technical promotion to dominate a niche market; the preview teases strategy—get the full 4P's Marketing Mix Analysis in an editable, presentation-ready format to save hours, apply real-world insights, and model competitive moves for clients or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopreservation Media Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioLife Solutions leads with CryoStor and HypoThermosol, proprietary clinical-grade media that are chemically defined and protein-free, engineered to reduce preservation-induced delayed-onset cell death and improve post-thaw viability for CGT materials.\u003c\/p\u003e\n\u003cp\u003eBy year-end 2025 these media remain the industry gold standard, cited in \u0026gt;60% of CAR-T and gene therapy INDs and driving BioLife’s preservation segment revenue to about $145 million in FY2024, up 22% YoY.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Thawing Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ThawSTAR automated thawing line shifts clinics from manual water baths to sensor-driven thawing, cutting variability and technician error; BioLife reported ThawSTAR contributed to a 18% uplift in device revenue in FY2024 (ended Dec 31, 2024).\u003c\/p\u003e\n\u003cp\u003eSensors detect sample-specific endpoints and stop heating, ensuring consistent thaw times across sites so potency of regenerative medicines is preserved; studies show automated thawing reduces potency loss by ~30% vs water baths.\u003c\/p\u003e\n\u003cp\u003ePrecision at point-of-care lowers batch failures and cold-chain losses; with average regenerative therapy vials valued at $25,000–$150,000, even a 1% reduction in loss saves $2.5M–$15M per 10,000 vials shipped.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSextant Lab Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSextant Lab Services, part of BioLife Solutions, offers specialized storage, fulfillment, and logistics for critical biological materials, supporting higher-margin recurring revenue after the 2021 strategic shift; in 2024 BioLife reported services revenue up 22% year-over-year, with services contributing roughly 34% of total revenue in Q3 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell Processing Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioLife Solutions product mix includes the d3 and Evo cell processing systems, engineered for handling and transporting biological payloads with payload capacity up to several liters and validated holding times exceeding 72 hours at controlled temperatures.\u003c\/p\u003e\n\u003cp\u003eThese tools integrate GPS tracking and multi-parameter environmental monitoring (temperature, humidity, shock), cutting reported cold-chain breaches by over 40% in 2024 pilot deployments.\u003c\/p\u003e\n\u003cp\u003eHardware creates auditable chain-of-custody records from lab to clinic, supporting compliance and reducing lost product value—BioLife cited recurring revenue growth of ~18% in 2024 tied to logistics solutions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrated monitoring: temp, humidity, shock, GPS\u003c\/li\u003e\n\u003cli\u003eValidated hold times: \u0026gt;72 hours\u003c\/li\u003e\n\u003cli\u003eReduced breaches: \u0026gt;40% in 2024 pilots\u003c\/li\u003e\n\u003cli\u003eRevenue link: ~18% recurring growth 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustom Formulation and OEM Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioLife offers custom media formulations and OEM services to big pharma, embedding its IP into partners’ manufacturing workflows for specific drug candidates and securing placement in clients’ regulatory filings.\u003c\/p\u003e\n\u003cp\u003eAs of 2025 BioLife reports \u0026gt;25 OEM partnerships and OEM-related revenue growing 28% year-over-year, supporting scale-up for cell and gene therapies and creating sticky, long-term revenue streams tied to regulatory dossiers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25+ OEM partners (2025)\u003c\/li\u003e\n\u003cli\u003eOEM revenue +28% YoY (2025)\u003c\/li\u003e\n\u003cli\u003eIP embedded in regulatory filings\u003c\/li\u003e\n\u003cli\u003eDrives long-term contract retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioLife grows preservation revenue 22% to $145M—services 34%, OEMs 25+, ThawSTAR +18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioLife’s product mix centers on CryoStor and HypoThermosol media, ThawSTAR thawing systems, d3\/Evo transport hardware, and Sextant services—driving FY2024 preservation revenue ~$145M (+22% YoY) and services contributing ~34% of revenue; OEM partnerships 25+ (2025) with OEM revenue +28% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCryo\/HypoThermosol\u003c\/td\u003e\n\u003ctd\u003e$145M rev (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThawSTAR\u003c\/td\u003e\n\u003ctd\u003eDevice rev +18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSextant\u003c\/td\u003e\n\u003ctd\u003eServices 34% rev (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM\u003c\/td\u003e\n\u003ctd\u003e25+ partners; +28% YoY (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into BioLife Solutions’ Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses BioLife Solutions’ 4P marketing insights into a concise, at-a-glance summary that’s ideal for leadership briefings or rapid internal alignment, helping teams quickly understand product positioning, pricing strategy, distribution channels, and promotional priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales to Biopharma and Academia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioLife Solutions deploys a global direct sales force focused on major biotech hubs and top academic centers, driving ~62% of 2024 product revenue through direct channels; reps provide on-site technical consultations and manage relationships with regenerative-medicine key opinion leaders (KOLs). This channel supported uptake in 38 ongoing Phase II\/III cell-therapy trials by mid-2025 and remains the primary driver of high-volume media adoption in clinical trials through end-2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distributor Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioLife Solutions uses a tiered global distributor network to reach markets where direct sales are inefficient, partnering with specialized life-science distributors such as STEMCELL Technologies to provide local inventory and logistics; in 2024 distributors accounted for roughly 28% of non-US revenue, helping serve 65+ countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Cold Chain Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioLife places products via partnerships with 3PL cold-chain leaders like Marken and World Courier, embedding its cryogenic media and TempGuard devices into their networks so items arrive ready-to-use at 95% of CGT clinical sites; in 2024 BioLife reported 18% revenue from logistics-linked sales, tying product adoption to transportation workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBioLife uses ecommerce and integrated procurement (ERP\/P2P) to speed repeat orders, cutting order-to-fulfillment time by ~30% and supporting ~24\/7 access for lab managers and procurement officers.\u003c\/p\u003e\n\u003cp\u003eThe digital storefront hosts technical docs and specs, reducing support tickets by 22% in 2024 and enabling bulk reorders for ~60% of recurring customers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 storefront—technical docs, specs\u003c\/li\u003e\n\u003cli\u003e~30% faster order fulfillment\u003c\/li\u003e\n\u003cli\u003e22% fewer support tickets (2024)\u003c\/li\u003e\n\u003cli\u003e60% recurring customers use bulk reorder\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Site Placement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThrough ThawSTAR device sales, BioLife Solutions places validated thawing systems inside hospitals and clinical trial sites, creating on-site reliance for cell and gene therapy workflows; as of 2025 the installed base exceeded 1,200 sites globally, boosting recurring consumable revenue.\u003c\/p\u003e\n\u003cp\u003eOnce installed, these devices generate a lock-in for proprietary consumables and protocols, with consumables contributing an estimated 25–30% of product-suite revenue and higher gross margins.\u003c\/p\u003e\n\u003cp\u003eThis decentralized placement at point of care secures presence at the final therapy delivery stage, shortening customer procurement cycles and raising switching costs for hospitals and sponsors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 installed sites (2025)\u003c\/li\u003e\n\u003cli\u003eConsumables ≈25–30% revenue\u003c\/li\u003e\n\u003cli\u003eIncreases switching costs, shortens procurement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioLife's multi‑channel engine: 62% direct, 1,200 ThawSTAR sites, 95% clinical readiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioLife places products via direct sales (≈62% product revenue, 2024), tiered distributors (28% of non-US revenue; 65+ countries), 3PL cold-chain partners (95% clinical-site readiness; 18% logistics-linked sales, 2024), ecommerce\/ERP (≈30% faster fulfillment; 22% fewer support tickets) and ThawSTAR installs (~1,200 sites, 2025; consumables 25–30% revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003eShare of product revenue\u003c\/td\u003e\n\u003ctd\u003e≈62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eGeographic reach \/ revenue\u003c\/td\u003e\n\u003ctd\u003e65+ countries \/ 28% non-US rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3PL partners\u003c\/td\u003e\n\u003ctd\u003eClinical-site readiness \/ revenue\u003c\/td\u003e\n\u003ctd\u003e95% \/ 18% logistics-linked\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEcommerce\/ERP\u003c\/td\u003e\n\u003ctd\u003eFulfillment \/ support impact\u003c\/td\u003e\n\u003ctd\u003e≈30% faster \/ −22% tickets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThawSTAR installs\u003c\/td\u003e\n\u003ctd\u003eInstalled base \/ consumables rev\u003c\/td\u003e\n\u003ctd\u003e≈1,200 sites \/ 25–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eBioLife Solutions 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual BioLife Solutions 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises; it’s fully complete and ready to use for strategy or presentation.\u003c\/p\u003e\n\u003cp\u003eThis is the same editable, high-quality file included with your order, covering Product, Price, Place, and Promotion with actionable insights tailored to BioLife Solutions.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing the exact version available for immediate download after checkout—buy with full confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750241972601,"sku":"biolifesolutions-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biolifesolutions-marketing-mix.png?v=1772223483","url":"https:\/\/matrixbcg.com\/products\/biolifesolutions-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}